Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terlipressin for Renal Perfusion in Septic Shock
NCT04948372Completed
- Sponsor
- Southeast University
- Start
- Sep 2019
- Primary completion
- May 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of terlipressin in septic shock (2 arms), sponsored by Southeast University. Primary endpoint: Peak sonographic signal intensity at 24 hours. Started Sep 2019; status: completed.
02
Drugs
terlipressin
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT04948372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04948372.